Spermosens goal is to improve male fertility diagnostics and treatment through the introduction of ground breaking products. Spermosens first patented product JUNO-Checked measures the binding capacity between sperm and egg cell, which is a prerequisite for natural fertilization. The results are deemed to be able to help doctors choose the appropriate treatment method, which contributes to more successful IVF treatments, reduced suffering, and increased quality of life. 

The WHO estimates that more than 48 million couples are affected by infertility, half of which is caused in whole or in part by a male factor. The company's shares are listed on Spotlight Stock market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com

Spermosens AB

Org chart

Teams

Offices